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Abstract 
Background: Huntington disease (HD) is a neurological disorder that causes severe motor 
symptoms that adversely impact health-related quality of life. Patient reported physical function 
outcome measures in HD have shown cross-sectional evidence of validity, but responsiveness 
has not yet been assessed. 
Objectives: This study evaluates the responsiveness of the Huntington Disease Health-Related 
Quality of Life (HDQLIFE) and the Quality of Life in Neurological Disorders (Neuro-QoL) 
physical function measures in persons with HD. 
Methods: Three-hundred and forty-seven participants completed baseline and at least one 
follow-up (12- and 24-month) measure (HDQLIFE Chorea, HDQLIFE Swallowing Difficulties, 
HDQLIFE Speech Difficulties, Neuro-QoL Upper Extremity Function, and/or Neuro-QoL Lower 
Extremity Function). Of participants that completed the baseline assessment, 338 (90.9%) 
completed the 12-month, and 293 (78.8%) completed the 24-month assessments. Standardized 
response means and general linear models evaluated whether the physical function measures 
were responsive to self-reported and clinician-rated change over time. 
Results: Small to moderate effect sizes for standardized response means supported 12 and 24-
month responsiveness of the HDQLIFE and Neuro-QoL measures for those with either self-
reported or clinician-rated declines in function. General linear models supported 12- and 24-
month responsiveness for all HRQOL measures relative to self-reported declines in health, but 
generally only 24-month responsiveness was supported relative to clinician-rated declines in 
function. 
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Conclusions: Longitudinal analyses indicate that the HDQLIFE and the Neuro-QoL physical 
function measures are sensitive to change over time in individuals with HD. Thus, these scales 
exhibit evidence of responsiveness and may be useful outcome measures in future clinical 
trials. 
 
Keywords: health-related quality of life, Huntington’s disease, patient reported outcome (PRO), 
psychometric, validity 
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Introduction 
Huntington disease (HD) is a progressive neurodegenerative disorder that causes 
profound cognitive, behavioral, and motor decline.1-6 The motor disorder in HD is multifaceted 
and can include chorea, bradykinesia, rigidity, and dystonia; these symptoms adversely impact 
all body segments and limbs, with significant impact on daily living and social participation.7 In 
HD clinical trials, most motor outcomes are administered by clinicians (e.g., UHDRS Total Motor 
Score) but these measures correlate poorly with real-world function.8 Patient-reported outcome 
(PRO) measures of motor symptoms and associated functional limitations are rarely used in 
HD, even though such outcomes are key measures of efficacy for new treatments.9 In HD, 
where many therapies under development seek to slow the loss of function related to motor 
problems,10-15 there is need for meaningful and sensitive PRO measures that capture physical 
aspects of health-related quality of life (HRQOL).  
The Huntington Disease Health-Related Quality of Life (HDQLIFE) measurement 
system16-18 was designed to provide reliable and valid assessments of HRQOL in persons with 
HD. This system includes several HD-specific measures of HRQOL as well as generic HRQOL 
measures from the Quality of Life in Neurological Disorders (Neuro-QoL) system.19,20 In a large 
cross sectional study of persons affected with prodromal/premanifest, early-, and late-stage HD, 
the HDQLIFE physical function PROs demonstrated strong validity and reliability;21 however, 
responsiveness over time has not yet been established. It is essential to determine the efficacy 
of experimental treatments, responsiveness, or the ability of a measure to detect meaningful 
change.22 In the current study, we follow the same population out for two years to determine 
whether these PROs can detect change over time. We hypothesized that the HDQLIFE and 
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Neuro-QoL measures would be responsive to self-reported global changes and clinician-rated 
changes in health. Specifically, we hypothesized that: 1) 12- and 24-month change would be 
greater in magnitude for those with self or clinician-rated declines in health relative to those 
reporting no change/improved health ; 2) there would be small to moderate 12- and 24-month 
effect sizes for participants with declines in health (based on either self-report or clinician 
ratings), negligible effect sizes for the group reporting no change, and negligible or small effect 
sizes for the group reporting improvements in physical health; and 3) there would be significant 
declines in PRO reports of physical HRQOL over time (for those individuals with self-reported 
declines or clinician-rated declines), whereas participants with no change or improvement in 
physical health would have no change, or no change/small improvements, respectively. 
Method 
Study Participants 
Data were collected through the HDQLIFE study, a longitudinal study examining HRQOL 
in persons affected with HD.17 Participants were included in analyses if they completed at least 
one follow-up visit (n=372 participants). A detailed description of the broader cohort study 
sample and recruitment methods are reported elsewhere.17 Study eligibility included a positive 
gene test and/or a clinical diagnosis of HD, as well as participant age of ≥ 18 years, and ability 
to provide informed consent (cognitive status was confirmed using a standard assessment23).  
Study Procedures 
Participants completed assessments at baseline and at 12- and 24-months. Each visit 
involved an in-person assessment and several computer-based self-report surveys regarding 
HRQOL, which could be completed during the in-person visit or at home. A subsample of 
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participants (n=24) participated in a 1 to 3 day retest of the self-report measures. All data were 
procured in accordance with the local institutional review boards, and participants provided 
informed consent prior to participation in this study.  
Measures 
 Clinician-Rated Assessments. All clinician-rated assessments were completed at each 
study visit. The Unified Huntington Disease Rating Scale (UHDRS)24 was used to classify 
participants in this study. The final question on the UHDRS Total Motor Scale asks the rater to 
score a diagnostic confidence level (DCL) for the participant, on a scale of 0 (Normal) to 4 
(symptoms unequivocal of HD with >99% certainty), to determine whether the participant has 
motor symptoms consistent with manifest HD. If the participant scored less than a 4, they were 
rated as having premanifest HD. Participants whom opted to complete follow-up visits by 
telephone (~15% of the study sample), did not complete the Total Motor Scale at follow-up. The 
UHDRS Total Functional Capacity (TFC) scale was used to determine stage for manifest HD 
participants. TFC scores range from 0-13, with higher scores indicating better function. 
Participants scoring between 7-13 on the TFC were classified as early-HD while those scoring 
between 0-6 rated were classified as late-HD.7,25 Baseline data was used to determine HD 
staging data for all analyses. 
The TFC was also used to characterize clinician-rated longitudinal change. Baseline 
TFC scores were subtracted from 12-month and 24-month scores, respectively to generate 
clinician- rated change scores in functioning for baseline to 12 months (M = -0.44; SD =1.49) 
and baseline to 24 months (M = -0.57; SD = 2.07). The distribution of change scores were used 
to classify participants into three groups: those with declines in functioning (i.e., TFC scores that 
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got worse at follow-up 1 SD greater than the sample; e.g., <-1.93 from baseline to 12-months 
and <-2.63 from baseline to 24-months), those with no change in functioning, or those with 
improvements in functioning (i.e., TFC scores that improved at follow-up 1 SD greater than the 
sample; e.g., >1.05 from baseline to 12-months and >1.50 from baseline to 24-months). This 
resulted in n=69 participants with declines, n=238 with no change, and n=23 with improvements 
in clinician ratings for baseline to 12-months, as well as n=45 participants with declines, n=216 
with no change and n=28 with improvements in clinician ratings for baseline to 24-months. 
Self-Reported Assessments. Participants provided information about age, gender, 
marital status, race, and ethnicity. Additionally, medical record data were used to confirm HD 
diagnosis and CAG repeat length for study participants.  
Physical HRQOL was assessed using physical health measures from the HDQLIFE16-18 
and Neuro-QoL measurement systems. Specifically, we examined HDQLIFE Chorea26 (which 
assesses the impact that chorea has on physical activity and participation), HDQLIFE Speech 
Difficulties27 (which assesses how difficulty with speech--i.e., oral expression, language 
production, and articulation affects communication and well-being), HDQLIFE Swallowing 
Difficulties27 (which assesses how problems with swallowing and choking impacts well-being 
and eating), Neuro-QoL Upper Extremity Function (which measures fine motor tasks and 
activities of daily living), and Neuro-QoL Lower Extremity Function (which measures mobility). 
The administration format for the HDQLIFE measures changed over the course of the study. 
Specifically, for the 259 participants (69.6% of the overall sample) completing all three study 
visits, 112 (43.2%) completed the full item pools for each HDQLIFE measure (64 items for 
Chorea, 27 items for Speech Difficulties, and 20 item for Swallowing Difficulties) and 147 
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(56.8%) completed the full item pools at the baseline and 12-months, but switched to answering 
assessments as computer adaptive tests (CATs) plus short forms (SFs) at their 24-month visit. 
Of the 79 participants that only completed the baseline and 12-month assessments (but not the 
24-month assessment), all completed the full item pools. Finally, of the 34 participants that only 
completed the baseline and 24-month assessments, 11 (32.4%) completed the full item pools at 
both assessments and 23 (67.6%) switched to the CATs plus SFs administration at their 24-
month visit. All Neuro-QoL measures were administered as a CAT plus SF at each time point. 
All HDQLIFE and Neuro-QoL scores are on a T-metric (M=50, SD=10); higher scores indicate 
more of the construct being assessed (i.e., high scores for HDQLIFE measures indicate worse 
physical HRQOL, whereas high scores on Neuro-QoL measures indicate better physical 
HRQOL). CAT scores were simulated for participants that completed the full item pools (rather 
than CAT administrations) using Firestar software.28 The CAT and SF administration of these 
measures takes one minute or less to complete.29 
At each follow-up visit (i.e., 12- and 24-months), participants rated 5 anchor items (one 
for each of the 3 HDQLIFE and 2 Neuro-QoL measures) on a 5-point Likert scale, ranging from 
1 (much worse) to 5 (much better), based on how they felt their condition was compared to the 
prior visit (Supplemental Table A). Each anchor item asked the participant about changes in 
either their chorea, speech, swallowing, ability to move their hands (i.e., upper extremities), or 
overall physical functioning (i.e., lower extremities). Based on their responses to each anchor 
item, participants were placed in three groups. Individuals who responded 1 (much worse) or 2 
(worse) were included in the group with self-reported declines in health. Participants who 
responded 3 (same) were included in the group with no changes in health. Participants who 
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responded 4 (better) or 5 (much better) were included in the group with improvements in health. 
To examine change from baseline to 24-month (for which there was no specific anchor), we 
classified participants who reported poorer function during any of the visits in the poorer self-
reported health group, those who did not report any changes between visits into the self-
reported no change group, and participants who reported improved functioning during any of the 
visits were placed in the self-reported improvement group. In the case that a participant reported 
improvement at one follow-up visit and decline in another, the ratings were offset and the 
participants was placed in the no change group. 
Statistical Analysis  
Descriptive Data. Statistical analyses were performed using SAS 9.4 software.30 The 
data were normally distributed (according to Bulmer’s criteria)31 and therefore we used 
parametric tests to analyze the data. Group differences for demographic variables were 
examined using either chi-square (for categorical data; Fisher’s Exact tests when cells counts < 
5) or one-way analysis of variance (ANOVA; for continuous data). Descriptive data for each 
HRQOL measure were calculated for each HD group (premanifest, early-HD, late-HD). One-
way ANOVA with Bonferroni post-hoc analyses determined whether the 3 HD groups differed on 
the 5 HRQOL physical health measures at each of the three assessments (baseline 12-, and 
24-months). We expected that the premanifest group would reported better physical HRQOL 
than the Early-HD group, who in turn would report better physical HRQOL than the Late-HD 
group.  
Reliability and Measurement Error. Intraclass correlation coefficients (ICC; random two-
way consistency model) were calculated to examine 1 to 3 day test-retest reliability for the small 
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subsample of participants; 95% confidence intervals (CI) were calculated for each reliability 
coefficient. Minimum acceptable criteria for test-retest reliability was set at ≥0.70 for intraclass 
correlations.32  
In addition, minimal important difference (MID), detectable change (DC95), and standard 
error of measurement (SEM) were calculated for the HDQLIFE and Neuro-QoL physical function 
measures. MID, or the smallest score change that are perceived as being important,33,34 were 
calculated using the means and standard deviations of participants who indicated that their 
physical function was either “a little worse,”  or “a little better” from baseline to 12-months (the 
absence of an anchor item to assess change from baseline to 24 months precluded the 
calculation of MIDs for this time frame). One-way ANOVA with Bonferonni post-hoc 
comparisons were used to determine if group differences were significant. DC95 was calculated 
as a conservative estimate and identify reliable change scores (i.e., the amount of change due 
that can be detected with 95% confidence as not due to measurement error) from baseline to 
12-months. DC95 was calculated according to the following formula:35  
𝐷𝐷𝐷𝐷95 = 𝑆𝑆𝑆𝑆𝑆𝑆 ∗ 1.96 ∗  √2. 
Finally, SEMs were calculated to estimate the maximum difference between one’s 
observed score and their true score for a given assessment.36 SEM was calculated using the 
baseline data as follows:   
𝑆𝑆𝑆𝑆𝑆𝑆 = 𝑆𝑆𝐷𝐷 ∗  √1 − 𝐼𝐼𝐷𝐷𝐷𝐷 
where SD is the standard deviation of the sample and ICC is the test-retest reliability of the 
measure. SEM percentages (SEM divided by the mean of all observations across time-points 
times one-hundred) < 10% are indicative of good measurement error.37  
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Responsiveness. Guyatt’s Responsiveness Statistic (RS) and Standardized Response 
Mean (SRM) effect sizes were calculated to examine the responsiveness of the HRQOL 
measures.  RS were calculated by dividing the mean change of each group by the standard 
deviation of change in the “no change” group.38  RS were calculated relative to self-reported and 
clinician-rated changes in physical health. SRMs were calculated by dividing the average 
change from baseline to follow-up (12- and 24-month) by the standard deviation of the 
change.39,40 SRMs were also calculated relative to self-reported and clinician-rated changes in 
physical health. For self-reported changes in health, we compared participants with self-
reported declines in health to those with no change and those with improvements in health. For 
clinician-rated changes in health we compared participants with clinician-rated declines in 
function relative those with no change or those with improvements in clinician-rated function. 
Given findings in other clinical samples,41 we hypothesized that RS and SRM effect sizes would 
be greater in magnitude for those who reported (or with clinician-rated) declines in health 
relative to those reporting no change/improved health. Effect sizes between 0.00 and |0.19| 
were considered “negligible”, |0.20| to |0.49| were small, |0.50| to |0.79| were moderate, and ≥ 
|0.80| were large.39 We hypothesized that participants who reported declines in health would 
have effect sizes ≤-0.20 for positively worded concepts (i.e., higher scores indicate better 
HRQOL), or ≥ 0.20 for negatively worded concepts (i.e., when higher scores indicate worse 
HRQOL). For participants that reported no change we predicted they would have negligible 
SRMs (i.e., ≥|0.19|). For the group with improvements in either self-reported health or clinician 
rated function, we predicted that RS/SRMs would be either small (i.e., 0.20 to 0.49; we expected 
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positive RS/SRMs for positively worded concepts and negative RS/SRMs for negatively worded 
concepts) or negligible (RS/SRMs ≥|0.19|); this hypothesis is based on previous literature that 
suggests globally reported improvements in HRQOL are smaller in magnitude that global ratings 
of declines.41 
 General linear models (GLMs) were used to examine change over time (from baseline 
to 12-months and baseline to 24-months) for each of the HDQLIFE and Neuro-QoL HRQOL 
measures relative to the respective self-reported anchor item or clinician-rated change. Each 
model included group status (i.e., declines in health, no change in health, or improvements) as a 
predictor of change in HRQOL. Least-square means and standard errors were calculated for 
each group to determine whether change over time significantly differed from zero. 
Responsiveness would be supported by significant declines in HRQOL relative to self-reported 
declines in health and clinician-rated declines in function. 
We provide a summative table of the different analytical approaches examining 
responsiveness of the physical HRQOL measures. For each HRQOL measure, responsiveness 
will be supported if ≥75% of results are in accordance with the proposed hypotheses.42 
Results 
Study Attrition 
At baseline, 152 participants had premanifest HD, 153 were early-stage, and 67 were 
late-stage HD. Of the 152 premanifest participants, 110 (72.4%) had a DCL 0f 0-1, while 42 
(17.6%) had a DCL of 2-3 (prodromal). A total of 338 individuals (90.9%) completed the 12-
month assessment, and 293 (78.8%) completed the 24-month assessment. Of those 
participants that were missing the 24-month visit (n=78), 34 were lost to follow-up, 15 were 
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unable to return or ineligible due to worsening symptoms, 12 withdrew consent or were unwilling 
to return, and 17 were lost due to “other” reasons (e.g., death, multiple reasons for termination, 
terminated by examiner). When compared to participants who completed all three assessments, 
the participants who did not complete the 24-month assessment were more likely to have Late-
HD (X22=23.4; p<.0001). Additionally, those who dropped out were more likely to be African 
American than other races (Fisher’s Exact p=.0132) or have a higher number of CAG repeats 
(OR=1.12; p=.0005). 
Descriptive Data 
Demographic characteristics for study participants are provided in Table 1. There were 
significant differences among the HD groups for each of the physical HRQOL measures at 
baseline, 12-, and 24-months (Supplemental Table B). In all cases, group differences were in 
the hypothesized direction (i.e., the premanifest group reported better physical HRQOL than the 
early-group, who in turn also reported better physical HRQOL than the late-HD group).  
Reliability and Measurement Error 
One to three day test-retest reliability for the HDQLIFE and Neuro-QoL measures was 
excellent. All ICC’s were > 0.85 (Supplemental Table B). MID and MCDs are presented in Table 
2; MIDs generally ranged from 1 to 3 points depending on the measure and group that was 
being examined (the largest MIDs were seen for the groups with declines), whereas MDC95 
values ranged from 4 to 11 points. All SEM values were < 10% indicating that measurement 
error was within acceptable limits (Table 2).  
Responsiveness 
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Table 3 displays 12- and 24-month RS of physical HRQOL measures, relative to self-
reported changes in physical health and clinician-rated changes in function. Effect sizes were 
consistent with the proposed hypotheses: they were greater in magnitude for those who self-
reported declines in health relative to those with no changes or self-reported improvements in 
health and they were greater in magnitude for those with clinician-rated declines in function 
relative to those with no changes or improvements in clinician ratings of function. For self-
reported change, effect sizes were generally negligible for the group reporting no change 
regardless of time frame (as hypothesized). For those with self-reported improvement, effect 
sizes were also generally negligible or small (in the hypothesized direction) for both the 12- and 
24-month time frames (as hypothesized). For those with self-reported declines in physical 
health, effect sizes were generally small regardless of time frame (again as hypothesized). A 
similar pattern of results was seen for self-reported change using SRM (see Supplemental 
Table C). 
For clinician-rated change, there were generally negligible effect sizes for the group with 
no change and the group with improvement for the baseline to 12-month time frame (as 
hypothesized), and there were generally small effect sizes for the group with clinician-rated 
declines (as hypothesized). From baseline to 24-months, there were typically negligible to small 
effect sizes for the groups with no change or improvement, and small effect sizes for those with 
declines. Again, a similar pattern of results was seen for the clinician-rated change using SRM 
(see Supplemental Table C). 
 Findings for the GLMs are included in Table 4. Twelve- and 24-month responsiveness 
was supported for all HRQOL measures relative to self-reported declines in health. In addition, 
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while 24-month responsiveness for all of the physical HRQOL measures was supported relative 
to clinician-rated declines in function, 12-month responsiveness was generally not supported 
relative to clinician-rated declines (notable exceptions included supported for 12-month 
responsiveness for Swallowing Difficulties [SF only], Upper Extremities [CAT and SF], and 
Lower Extremities [CAT and SF]). As hypothesized, participants with no change or 
improvements in physical health (based on both self-reported and clinician-ratings), did not have 
significant 12-month changes on the HRQOL measures. Furthermore, the group with 
improvements (based on both self-reported and clinician-ratings) also generally did not have 
significant 24-month change on the HRQOL measures (as hypothesized). Finally, with regard to 
24-month responsiveness, and not as expected, the no change group (based on both self-
reported and clinician-ratings) generally had changes in HRQOL score, albeit these changes 
were small. 
Discussion 
This investigation provides evidence that the HDQLIFE and Neuro-QoL Physical 
Function measures demonstrate responsiveness to health status changes for persons with HD. 
The majority of the HDQLIFE and Neuro-QoL physical HRQOL measures met our a priori 
criterion for responsiveness (see the Supplemental Table D). First, 12- and 24-month effect 
sizes for patient-reported physical health were larger for individuals with worsening health 
relative to participants with no change or improvements in physical health; this was true for self-
reported decline and clinician-rated decline. Our results are consistent with the responsiveness 
of the Neuro-QoL measures in other neurological conditions, including Parkinson’s disease and 
adult epilepsy.43-45 
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In addition, while the group with self-reported and clinician-rated declines exhibited small 
declines in physical HRQOL at 12-month and 24-month- which is typical for PRO measures - 
there were a few measures that were especially responsive to declines in physical HRQOL. 
Relative to self-reported declines in health, Swallowing Difficulties and Upper Extremities 
exhibited moderate effect sizes for both 12- and 24-month change over time. Relative to 
clinician-rated functional declines, Swallowing Difficulties and Upper Extremity Function were 
again noteworthy with regard to 24-month change over time.  
As expected, there were negligible or small change over time on HRQOL scores for 
participants with self- and clinician-reported improvements in health. These findings are 
consistent with previous literature in other populations that find that global improvements in 
HRQOL - using PROs - tend to be significantly smaller in magnitude than those global ratings of 
decline.41 In addition, and also as expected, 12-month effect sizes were negligible for individuals 
with no self- or clinical-reported changes in health. Yet, contrary to the expectation of negligible 
change, there were generally small 24-month effect size declines for the group that did not 
change based on both self-report and clinician ratings. Thus, participants may experience small 
declines in HRQOL that either the patients and/or clinicians either are unable to detect and/or 
that do not affect function. 
Some measures did not perform as well as expected. Although 24-month 
responsiveness for all of the physical HRQOL measures was supported relative to clinician-
rated declines in function, support for 12-month responsiveness relative to clinician-rated 
declines was less robust. We believe that the large variability in TFC-related change (i.e., large 
standard errors) was likely responsible for the absence of significant 12-month group 
This article is protected by copyright. All rights reserved.
differences. Specifically, individuals with larger TFC-related declines are also more likely to 
have advanced disease and the reliability of PRO scores are adversely affect by cognitive 
impairment.46  
Our responsiveness data were more robust when examining self-reported HRQOL 
relative to self-reported change and less robust when examining self-reported HRQOL relative 
to clinician-rated changes. Findings from other populations suggest that clinicians tend to 
systematically underestimate patient symptoms and functional decline.47-55 This is not an issue 
when both the patient and clinician are providing similar reports for functional abilities and 
symptoms, but in cases where clinicians and patients are discordant, the path forward may be 
less clear. It may be that this discrepancy is simply a disagreement between the patient and the 
clinician about the relative importance of an aspect of function, but HD patients are also less 
able to communicate their problems as the disease progresses. Importantly, PROs and 
clinician-ratings provide different information; the overall concordance (or lack thereof) between 
these reports may provide clinically meaningful information. Given this, and the fact that PROs 
are not typically included in HD clinical care, clinicians may miss important patient-centered 
information by relying primarily on clinician ratings of disease progression. Including PROs can 
help clinicians better care for patients by providing a more complete picture. MIDs and MCDs 
provided in Table 2 can be used to help guide clinical interpretation of change scores on these 
PROs. 
Our study has some limitations. With regard to the study procedures, a small portion of 
the sample completed follow-up assessments via telephone, and thus clinician-ratings for 
several measures were missing for these participants.  While there is data to support the 
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equivalence of the different administration formats,56-58 it is also important to acknowledge that 
the administration format for the HDQLIFE measures was not consistent across study visits (as 
detailed above).  Also, participants with more advanced disease were more likely to be lost to 
follow-up, and differential attrition may have made it more difficult to identify significant declines 
in physical HRQOL. This is not an uncommon problem in HD, and most studies (including 
clinical trials) target individuals that are either premanifest or early in the disease process.59-61 
Potential strategies to help mitigate loss to follow-up can include engaging advocacy groups, 
participation in HD community events, and engagement of social media.62,63 Given that 
individuals with more severe disease were more likely to discontinue participation due to 
worsening symptoms (and in many cases the inability to provide informed consent at a latter 
study visit), and that these individuals are precisely the individuals that are experiencing the 
largest declines in health, we would expect this to negatively impact our findings such that effect 
sizes are smaller than would be expected for the HD population. This would be consistent with 
findings in this sample that suggest that reliability of these PROs can be compromised in those 
in the later stages of the disease process.64 Our results are based on a well-educated, primarily 
non-Hispanic white population, limiting possible generalizability to other racial/ethnic groups. In 
addition, self-reported changes were also closely matched to each physical HRQOL domain, 
whereas clinician-rated changes reflected functional changes - which are less closely tied to 
HRQOL constructs - precluding our ability to directly compare the clinical utility of these 
measures across these two different types of anchors. In addition, we did not collect data about 
therapeutic treatments for study participants, and thus the impact of current therapeutic 
treatments is currently unknown. Furthermore, given that the baseline data informed the 
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development of the HDQLIFE CAT and SF administrations, the baseline and 12-month study 
visits included significantly more items than the 24-month study visit (when most participants 
were able to complete the shorter administration formats of these measures).  
Finally, changes over time were modest, as demonstrated by the small MIDs (Table 2). 
As often happens, MIDs were generally smaller than the associated DC95 for each measure. 
Use of DC95 to classify people as changed is a useful conservative approach when one wishes 
to be 95% confident that change has occurred. However, if the goal is to optimize accurate 
classification, then a value closer to the MID is likely to be more accurate.  
Taken together, findings support the responsiveness of the HDQLIFE and Neuro-QoL 
physical HRQOL measures to change over time. We observed small to moderate effect sizes in 
the absence of an intervention designed to improve HRQOL, so these analyses likely provide a 
conservative estimate of psychometric performance. As such, data would support using these 
new measures of HRQOL in both observational and experiemental research study designs in 
persons with HD, in conjunction with the more commonly administered clinician-rated measures 
of physical functioning. Findings also highlight the importance of complementing clinician-ratings 
with patient-report of HRQOL to better understand the impact that an intervention has on an 
individual affected with HD. In this manner, a more patient-centered approach to HD treatment 
should include an assessment of health-related quality of life. As such, HRQOL physical 
function measures have the potential to provide clinically relevant information that should be 
considered in the context of the standard clinical exam (which does not typically include PROs) 
in persons with HD. 
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Table 1 
 
Baseline descriptive data 
 
Variable Premanifest-HD Early-HD Late-HD 
Combined 
Sample 
  (N=152) (N=153) (N=67) (N=372) 
Age (Years)*     
M (SD) 43.0 (12.4) 53.0 (11.9) 55.0 (10.7) 49.3 (13.0) 
Gender (%)     
Female 64.5 53.6 56.7 58.6 
Male 35.5 46.4 43.3 41.4 
Race (%)*     
White 98.0 95.4 92.5 95.8 
African American 0.0 1.3 7.5 1.9 
Other 1.3 3.3 0.0 1.9 
Unknown 0.7 0.0 0.0 0.3 
Ethnicity (%)     
Not Hispanic or Latino 92.1 91.5 97.0 92.7 
Hispanic or Latino 1.3 5.2 0.0 2.7 
Not Provided 6.6 3.3 3.0 4.6 
Education (# of years)*    
M (SD) 16.1 (2.8) 14.8 (2.8) 14.1 (2.5) 15.2 (2.8) 
Marital Status (%)     
Single, Never Married 15.1 15.2 9.0 14.1 
Married 69.1 57.6 65.7 63.8 
Separated/Divorced 13.2 19.9 22.4 17.6 
Widowed 0.0 3.3 3.0 1.9 
Living with Partner 2.6 4.0 0.0 2.7 
# Converted (Baseline 
to 12-months) 8 12 -- 19 
# Converted (Baseline 
to 24-months) 16 43 -- 57 
CAG Repeats     
M (SD) 41.9 (2.6) 42.8 (3.9) 43.9 (6.3) 42.5 (3.7) 
Note. HD = Huntington disease. * indicates significant group differences: premanifest 
participants were on average 10 years younger than the Early-HD group and 12 years 
younger than the late-HD group (F[2,344]=37.63; p<.0001); the premanifest group had 
approximately one more year of attainment in education (F[2,337]=13.4;p<.0001); the 
Late-HD group had a significantly higher proportion of African Americans than the other 
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two groups (Fisher’s Exact p=.0048). # Converted indicates the number of participants 
who moved to next stage from baseline to follow-up. Baseline to 24-month conversion 
also includes those who converted from 12- to 24-month. 
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Table 2 
12-month Minimal Important Differences, Minimum Detectable Change, and Standard Error of Measurement 
 
MID 










Chorea CAT 1.03 (4.33) -0.47 (5.63) 7.80 (-7.40, 8.20) 2.81 5.71 
Chorea SF 0.89 (4.90) 0.18 (6.42) 7.54 (-7.04, 8.04) 2.72 5.49 
Speech Difficulties CAT 1.36 (6.53) -1.43 (7.99) 5.91 (-5.61, 6.21) 2.13 4.41 
Speech Difficulties SF b 1.15 (6.19) -3.36 (7.78) 7.28 (-7.18, 7.38) 2.62 5.42 
Swallowing Difficulties CAT a 2.62 (4.46) -1.00 (6.68) 4.13 (-3.63, 4.63) 1.49 2.99 
Swallowing Difficulties SF a 2.76 (4.52) 1.08 (10.03) 5.77 (-4.77, 6.77) 2.08 4.18 
Upper Extremities CAT^ -2.56 (5.96) -0.41 (6.45) 5.65 (-6.75, 4.55) 2.04 4.59 
Upper Extremities SF^ a -2.87 (6.89) -1.17 (4.85) 10.58 (-12.08, 9.08) 3.82 8.62 
Lower Extremities CAT^ -2.12 (5.60) -0.46 (5.92) 7.55 (-8.25, 6.85) 2.73 5.62 
Lower Extremities SF^ -2.31 (5.72) -0.25 (7.16) 6.31 (-7.61, 5.01) 2.28 4.65 
Note: CAT=Computer Adaptive Test; SF=Short Form; MID=Minimal Important Difference; SEM=Standard Error of 
Measurement; DC95= Detectable Change (95% Confidence); ^ = higher scores indicate better HRQOL. LDC = Lower 
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Detectable Change (95% Confidence); UDC = Upper Detectable Change (95% Confidence); LDC and UDC calculated 
in reference to 12-month change in HRQOL 
a Health decline group differs from no change group 





Guyatt’s Responsiveness Statistics for changes in HRQOL 
 
 Self-Reported Changes in Physical Health (from anchor items) 
 
Baseline to 12-months Baseline to 24-months 
 
No Change in Health Declines in Health Improvement in Health No Change in Health Declines in Health Improvement  in Health 
N SRM N SRM N SRM N SRM N SRM N SRM 
Chorea CAT 223 0.10 74 0.26 24 -0.30 139 0.20 78 0.30 22 0.15 
Chorea SF 220 0.06 73 0.20 24 -0.19 137 0.21 77 0.44 22 0.27 
Speech Difficulties CAT 225 0.05 76 0.21 21 -0.24 142 0.14 83 0.28 18 -0.02 
Speech Difficulties SF 224 0.00 75 0.18 21 -0.35 144 0.12 81 0.26 18 -0.15 
Swallowing Difficulties CAT 239 0.03 64 0.58 21 -0.22 145 0.09 78 0.61 20 0.10 
Swallowing Difficulties SF 241 0.08 61 0.64 21 0.01 145 0.19 76 0.71 20 0.40 
Upper Extremities CAT^ 210 -0.11 80 -0.46 33 0.15 127 -0.36 90 -0.47 28 -0.12 
Upper Extremities SF^ 211 -0.12 80 -0.44 33 -0.02 128 -0.17 90 -0.43 28 -0.06 
Lower Extremities CAT^ 197 -0.14 63 -0.34 63 0.05 125 -0.29 66 -0.58 56 -0.06 
Lower Extremities SF^ 197 -0.13 63 -0.40 63 -0.06 125 -0.26 66 -0.46 56 0.08 
 Clinician-Rated Changes in Function (from TFC) 
 
Baseline to 12-months Baseline to 24-months 
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No Change in Health Declines in Health Improvement in Health No Change in Health Declines in Health Improvement  in Health 
N SRM N SRM N SRM N SRM N SRM N SRM 
Chorea CAT 238 0.06 68 0.22 23 0.20 216 0.24 45 0.31 28 -0.28 
Chorea SF 234 0.04 68 0.10 23 0.07 214 0.30 44 0.46 27 0.00 
Speech Difficulties CAT 236 0.01 68 0.17 23 -0.06 216 0.16 44 0.32 28 0.01 
Speech Difficulties SF 235 -0.03 68 0.14 23 -0.09 216 0.12 45 0.37 27 -0.11 
Swallowing Difficulties CAT 236 0.12 68 0.11 23 -0.25 216 0.17 44 0.53 28 0.33 
Swallowing Difficulties SF 236 0.15 69 0.30 22 -0.15 215 0.33 45 0.54 26 0.42 
Upper Extremities CAT^ 233 -0.05 66 -0.51 23 -0.04 215 -0.27 41 -0.75 26 -0.49 
Upper Extremities SF^ 235 -0.15 66 -0.41 23 0.24 217 -0.25 42 -0.42 26 0.11 
Lower Extremities CAT^ 233 -0.07 66 -0.39 23 0.07 215 -0.24 41 -0.53 26 -0.21 
Lower Extremities SF^ 234 -0.10 66 -0.44 23 -0.01 217 -0.28 42 -0.48 26 -0.07 
Note: CAT=Computer Adaptive Test; SF=Short Form; ^ = higher scores indicate better HRQOL; bolding indicates effects size magnitudes that are consistent with proposed hypotheses 
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 Table 4 
 
Responsiveness relative to self-reported changes in health and clinician-rated changes in function 
 
 





























 Self-Reported Changes in Physical Health (from anchor items) 
Chorea CAT 0.50 (0.33) 1.12 (0.57) -1.69 (1.01) 1.24 (0.51)* 1.66 (0.68)* 0.95 (1.28) 
Chorea SF 0.29 (0.35) 0.95 (0.61) -1.16 (1.06) 1.07 (0.46)* 2.53 (0.61)* 1.34 (1.14) 
Speech Difficulties CAT 0.25 (0.40) 1.36 (0.68)* -2.05 (1.30) 0.94 (0.56) 1.78 (0.73)* -0.20 (1.57) 
Speech Difficulties SF 0.02 (0.38) 1.12 (0.65) -2.95 (1.23)* 0.79 (0.53) 1.61 (0.71)* -1.02 (1.50) 
Swallowing Difficulties CAT 0.17 (0.39) 2.81 (0.76)* -1.81 (1.32) 0.59 (0.54) 3.55 (0.74)* 0.70 (1.46) 
Swallowing Difficulties SF 0.49 (0.39) 3.19 (0.77)* 0.14 (1.31) 1.14 (0.50)* 4.24 (0.69)* 2.44 (1.34) 
Upper Extremities CAT^ -0.65 (0.43) -2.76 (0.69)* 1.20 (1.08) -1.82 (0.51)* -3.01 (0.61)* -0.80 (1.09) 
Upper Extremities SF^ -0.71 (0.43) -3.03 (0.70)* -0.12 (1.08) -1.03 (0.57) -3.05 (0.68)* -0.39 (1.22) 
Lower Extremities CAT^ -0.77 (0.42) -1.94 (0.74)* 0.37 (0.74) -1.85 (0.58)* -3.72 (0.79)* -0.40 (0.86) 
Lower Extremities SF^ -0.69 (0.41) -2.24 (0.72)* -0.41 (0.72) -1.43 (0.53)* -3.25 (0.73)* 0.45 (0.79) 
 Clinician-Rated Changes in Function (from TFC) 
Chorea CAT 0.32 (0.32) 1.13 (0.59) 0.66 (1.02) 1.34 (0.40)* 2.24 (0.87)* -1.44 (1.11) 
Chorea SF 0.21 (0.34) 0.63 (0.63) 0.33 (1.08) 1.50 (0.37)* 3.23 (0.81)* -0.01 (1.03) 
Speech Difficulties CAT 0.08 (0.39) 1.31 (0.72) -0.38 (1.25) 1.04 (0.44)* 2.54 (0.98)* 0.05 (1.23) 
Speech Difficulties SF -0.14 (0.37) 1.03 (0.68) -0.54 (1.18) 0.73 (0.42) 2.71 (0.92)* -0.50 (1.19) 
Swallowing Difficulties CAT 0.66 (0.40) 0.87 (0.75) -1.36 (1.28) 0.97 (0.44)* 4.66 (0.97)* 2.33 (1.22) 
Swallowing Difficulties SF 0.77 (0.39) 2.43 (0.73)* -0.95 (1.28) 1.74 (0.41)* 4.58 (0.89)* 2.72 (1.17)* 
Upper Extremities CAT^ -0.28 (0.40) -3.71 (0.76)* -0.19 (1.28) -1.45 (0.38)* -5.19 (0.88)* -2.77 (1.10)* 
Upper Extremities SF^ -0.86 (0.40)* -3.19 (0.76)* 1.29 (1.29) -1.56 (0.44)* -3.43 (1.00)* 0.56 (1.27) 
This article is protected by copyright. All rights reserved.
Lower Extremities CAT^ -0.41 (0.38) -2.62 (0.72)* 0.35 (1.22) -1.41 (0.43)* -4.33 (0.98)* -1.41 (1.24) 
Lower Extremities SF^ -0.53 (0.37) -2.87 (0.70)* -0.03 (1.18) -1.44 (0.40)* -3.67 (0.92)* -0.55 (1.16) 
Note: *Denotes that change significantly differs from 0 (p<.05); Higher scores indicate worse HRQOL unless indicated. ^Indicates that 
measure is reverse scored (i.e., higher scores indicate better HRQOL) 
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